In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bieber Becomes Biopharmaceuticals Development Head At Sandoz

Executive Summary

Florian Bieber is to become head of development for Sandoz’ biopharmaceuticals division, after Mark Levick agreed to take up the post of CEO at Alvotech.

You may also be interested in...



Sandoz Biopharma Head Levick To Become CEO Of Alvotech

Mark Levick, Sandoz’ head of development for biopharmaceuticals, has been chosen to become CEO of Alvotech from August.

Slowing Biopharmaceuticals Puts A Dent In Sandoz’ Sales

Slower sales growth by its Biopharmaceuticals unit amid competitive pressures in the US, combined with weakness in its Retail Generics and Anti-Infectives franchises, led Sandoz to report an overall 8% sales slide in the first quarter of this year. 

Novartis Selects GSK’s Saynor As Next Sandoz CEO

GlaxoSmithKline’s established products head, Richard Saynor, will return to Sandoz later this year to lead the Novartis division.

Topics

Related Companies

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel